Drug Trial Radar · NCT04435392
Jaktinib Hydrochloride Cream For Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Apr 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
107
Actual
Start
Oct 14, 2020
Primary completion
Sep 8, 2022
Study completion Sep 8, 2022
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes a dose escalation part and a dose extension part.
Conditions
- Atopic Dermatitis
Interventions
Jaktinib Hydrochloride CreamDrug
Subjects in each group were scheduled to give the drug for 8 weeks.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving Physician's Global Assessment (PGA) Response of Clear or Almost ClearTime frame: 7 days after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.